Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRx eyes new markets with appointment of Asian VP

"Jasmine's depth of experience in driving corporate IP strategies and business development, as well as bringing products to market in Asia, will be a huge asset to Volition," said CEO Cameron Reynolds.
Dr Kway will be based in Volition’s office in Singapore

VolitionRx Limited (NYSEMKT:VNRX) signalled its intention to expand into Asian markets with the appointment of Dr Jasmine Kway as its vice president of Asia.

The decision to expand its footprint follows Tuesday’s news that it had achieved CE marking on its Nu.QTM Colorectal Cancer Screening Triage Test, paving the way for its expected launch across the European Union.

Volition plans to bring the product to market in Europe this year and now has its sights on Asia.

The company, which is developing blood-based diagnostic tests for different types of cancer, will be working with Dr Kway to expand into the Asian markets with direct marketing to countries with screening programs as well as seeking the required approvals for use in the new Asian markets.

Volition said Dr Kway has a proven track record in achieving positive business results by developing strategic business alliances, identifying new markets, and developing business processes.

To date she has worked with numerous health and regulatory bodies across Asia and has successfully introduced numerous private sector companies into the Asian markets.

Prior to joining Volition, Dr Kway was chief executive officer of intellectual property practice at RHT i-Assets Advisory, one of the leading companies of the RHT Group of Companies, and RHT Holdings (RHT), a Singapore-headquartered integrated leading professional services company providing professional services in Asia.

She will be based in Volition’s office in Singapore.

Why Invest In VolitionRx? Read More Here

Register here to be notified of future VNRX Company articles
View full VNRX profile View Profile

VolitionRx Timeline

April 11 2017

Related Articles

In the six months ended March, revenues increased 31% to £2mln
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of an affimer
April 03 2017
Avacta has developed an innovative protein-scaffold platform, with potential applications in the life sciences research, diagnostic and therapeutic markets
Copyright ©, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use